Pulse Biosciences shares surge 46.75% after-hours on positive nPulse cardiac catheter study results.

Pulse Biosciences surged 46.75% in after-hours trading following the release of strong clinical data from its nPulse Cardiac Catheter first-in-human feasibility study. The company reported 96% procedural success at one year (45/47 patients) and 100% success at six months (75/75 patients), with rapid procedure times and minimal adverse events. These results, presented at the Annual AF Symposium 2026, highlight the nPulse system’s potential to advance atrial fibrillation treatment by offering rapid, non-thermal ablation with high efficacy. The data also showed 1.3% serious adverse events and average procedure times of 65 minutes, reinforcing the technology’s safety and efficiency. The announcement aligns with broader investor enthusiasm for biotech innovation and clinical validation, driving significant post-market volume and optimism about the device’s commercial potential.